menu
    • menu
    [{"orgOrder":0,"company":"Air Liquide Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Xenon","moa":"NMDA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Air Liquide Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Air Liquide Group \/ Undisclosed"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"Eurofins Biomnis | Monitoring Force Group | Inferential","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Xenon","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ Eurofins Biomnis | Monitoring Force Group | Inferential","highestDevelopmentStatusID":"10","companyTruncated":"Air Liquide Group \/ Eurofins Biomnis | Monitoring Force Group | Inferential"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Xenon","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Air Liquide Group \/ Orion Corporation"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"OptumInsight","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Xenon","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ OptumInsight","highestDevelopmentStatusID":"8","companyTruncated":"Air Liquide Group \/ OptumInsight"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"ORION Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase I","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ ORION Clinical Services","highestDevelopmentStatusID":"6","companyTruncated":"Air Liquide Group \/ ORION Clinical Services"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Helium","moa":"quaternary ammonium derivatives","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Air Liquide Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Air Liquide Group \/ Undisclosed"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"Asklepios Kliniken Hamburg","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Helium","moa":"quaternary ammonium derivatives","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Air Liquide Group \/ Asklepios Kliniken Hamburg","highestDevelopmentStatusID":"10","companyTruncated":"Air Liquide Group \/ Asklepios Kliniken Hamburg"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"AMS Advanced Medical Services","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"EMONO","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ AMS Advanced Medical Services","highestDevelopmentStatusID":"8","companyTruncated":"Air Liquide Group \/ AMS Advanced Medical Services"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"Fernando Suarez Sipmann","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ Fernando Suarez Sipmann","highestDevelopmentStatusID":"1","companyTruncated":"Air Liquide Group \/ Fernando Suarez Sipmann"}]

    Find Clinical Drug Pipeline Developments & Deals by Air Liquide Group

    Menu

    Air Liquide Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Sponsor : Fernando Suarez Sipmann

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Role of Inhaled Nitric Oxide in Vascular Mechanics and Right Ventricular Function

                            Details : Nitric Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Pulmonary Atelectasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2023

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Fernando Suarez Sipmann

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMONO

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : AMS Advanced Medical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMONO for the Treatment of Peripheral Neuropathic Pain

                            Details : EMONO is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuralgia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 08, 2016

                            Lead Product(s) : EMONO

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : AMS Advanced Medical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : ORION Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyperalgesia and Pain

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperalgesia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 20, 2012

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : ORION Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Helium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Asklepios Kliniken Hamburg

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Six-Minute Walk Test Comparing Helium/Oxygen to Nitrogen/Oxygen for COPD Rehabilitation

                            Details : Helium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2011

                            Lead Product(s) : Helium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Asklepios Kliniken Hamburg

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xenon

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Orion Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

                            Details : Xenon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 11, 2011

                            Lead Product(s) : Xenon

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Orion Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xenon

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : OptumInsight

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hip Fracture Surgery in Elderly Patients

                            Details : Xenon is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Delirium.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2010

                            Lead Product(s) : Xenon

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : OptumInsight

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Helium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disea...

                            Details : Helium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2010

                            Lead Product(s) : Helium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xenon

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Eurofins Biomnis | Monitoring Force Group | Inferential

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surg...

                            Details : Xenon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2010

                            Lead Product(s) : Xenon

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Eurofins Biomnis | Monitoring Force Group | Inferential

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Air Liquide Group

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xenon

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sympathetic Neural Outflow During Xenon Anesthesia in Humans

                            Details : Xenon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2010

                            Lead Product(s) : Xenon

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth